Get the Stockscreener App
2.34
1.68%
-0.04
After Hours:
2.35
0.01
+0.43%
Immunitybio Inc stock is traded at $2.34, with a volume of 6.10M.
It is down -1.68% in the last 24 hours and down -18.18% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.38
Open:
$2.38
24h Volume:
6.10M
Relative Volume:
0.70
Market Cap:
$2.21B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.4124
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+3.54%
1M Performance:
-18.18%
6M Performance:
-18.18%
1Y Performance:
-44.15%
1-Day Range:
$2.32
$2.42
1-Week Range:
$2.21
$2.425
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.34 | 2.25B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Signal strength of ImmunityBio Inc. stock in tech scannersJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.July 2025 Macro Moves & AI Forecasted Stock Moves - Newser
What the charts say about ImmunityBio Inc. todayEarnings Beat & Stepwise Trade Signal Implementation - Newser
Using Python tools to backtest ImmunityBio Inc. strategiesRecession Risk & Technical Pattern Recognition Alerts - Newser
Volatility clustering patterns for ImmunityBio Inc.Volume Spike & Free Risk Controlled Daily Trade Plans - Newser
What ImmunityBio (IBRX)'s Early Glioblastoma Disease Control Results Could Mean for Shareholders - Yahoo Finance
Chart based analysis of ImmunityBio Inc. trends2025 Momentum Check & Smart Money Movement Tracker - Newser
Combining machine learning predictions for ImmunityBio Inc.Portfolio Return Summary & Verified Momentum Stock Ideas - Newser
ImmunityBio Reports Promising Early Results in Glioblastoma Trial with 100% Disease Control Rate - AInvest
Analyzing recovery setups for ImmunityBio Inc. investorsJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - Newser
Reversal indicators forming on ImmunityBio Inc. stock2025 Geopolitical Influence & Growth Focused Entry Reports - Newser
Comparing ImmunityBio Inc. in custom built stock radars2025 Price Targets & Safe Entry Zone Tips - Newser
Using data tools to time your ImmunityBio Inc. exitDollar Strength & Free Real-Time Market Sentiment Alerts - Newser
ImmunityBio: D. Boral Capital Maintains Buy Rating with Raised PT to $24 - AInvest
Analyzing ImmunityBio Inc. with multi timeframe chartsJuly 2025 Institutional & Risk Controlled Daily Plans - Newser
What technical models suggest about ImmunityBio Inc.’s comebackQuarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma - Seeking Alpha
ImmunityBio Inc. stock prediction for this weekQuarterly Earnings Report & Technical Confirmation Trade Alerts - Newser
ImmunityBio Inc. Facing Inflection Point in Trend Analysis getLinesFromResByArray error: size == 0 - newsyoung.net
ImmunityBio stock surges after promising glioblastoma treatment results By Investing.com - Investing.com Canada
ImmunityBio stock surges after promising glioblastoma treatment results - Investing.com
ImmunityBio reports promising results in glioblastoma treatment trial - Investing.com
ImmunityBio's ANKTIVA and Optune Gio: A Dual-Immunotherapy Breakthrough in Recurrent Glioblastoma and Long COVID - AInvest
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Yahoo Finance
Applying Wyckoff theory to ImmunityBio Inc. stockJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - Newser
Will ImmunityBio Inc. continue its uptrendStock Surge & Reliable Momentum Entry Alerts - Newser
Is now a turning point for ImmunityBio Inc.Inflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Will ImmunityBio Inc. benefit from macro trendsJuly 2025 Update & AI Powered Market Entry Strategies - Newser
Live market analysis of ImmunityBio Inc.2025 Market Overview & Growth Focused Investment Plans - Newser
Published on: 2025-08-23 23:59:47 - Newser
Developing predictive dashboards with ImmunityBio Inc. data2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser
Real time scanner hits for ImmunityBio Inc. explainedMarket Trend Summary & High Conviction Buy Zone Alerts - Newser
Is ImmunityBio Inc.’s growth already priced in2025 Macro Impact & Consistent Return Strategy Ideas - 더경남뉴스
Day 5 of Loss Streak for ImmunityBio Stock with -20% Return (vs. -12% YTD) [8/20/2025] - Trefis
How ImmunityBio Inc. stock reacts to Fed policy changesJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - Newser
Vir Biotechnology shares rise 2.52% premarket after ImmunityBio's new Phase 2 trial launch. - AInvest
ImmunityBio shares rise 3.07% premarket after announcing Phase 2 study of ANKTIVA® for long COVID. - AInvest
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: D. Boral Capital keeps Buy, raises PT to $24 from $24. - AInvest
Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent
ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener
ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):